Overview

A Randomized, Double-blind, Placebo-controlled Evaluation of Increasing Doses of Weekly Tafenoquine for Chemosuppression of Plasmodium Falciparum

Status:
Completed

Trial end date:
2003-03-01

Target enrollment:

Participant gender:

Summary

This was a randomised, double-blind, placebo-controlled study to compare the efficacy of a range four weekly doses of tafenoquine, and weekly mefloquine, with placebo as chemosuppression of P. falciparum malaria. Medications and placebo were matched and a double-dummy technique enabled blinding of tafenoquine versus mefloquine.

Phase:

Phase 2

Details

Lead Sponsor:

U.S. Army Medical Research and Development Command
U.S. Army Medical Research and Materiel Command

Collaborator:

SmithKline Beecham

Treatments:

Mefloquine
Tafenoquine